MV130 confers protection by inducing trained immunity

January 2022

Results published in Cell Reports show that MV130 protects against respiratory viral infections by inducing Trained Immunity. This type of immunity generates memory and depends on the "training" of Innate Immune System cells. Trained immunity involves epigenetic and metabolic changes that make trained cells more effective against infections, including viral infections.
More info

MV130 protects and boosts vaccines against SARS-CoV-2

November 2021

According to the results published in Frontiers in Immunology, MV130 protects against experimental infection with SARS-CoV-2 in hACE2 transgenic mice. In addition, pretreatment with MV130 is shown to enhance the immunogenicity of candidate COVID-19 vaccines directed against viral protein S, enhancing both antibody and cell-specific responses.
More info

Allergoid-mannan conjugates on macrophages

Conjugados alergoidesOctober 2021

Allergy publishes a study showing that allergoid-mannan conjugates confer tolerogenic properties to human macrophages. These cells have been described to play a relevant role in the induction of allergen-specific tolerance in sublingual immunotherapy models, so this study may help to better understand the immunological mechanisms of allergy vaccines based on these glycoconjugates.
More info

MV140 results in recurrent UTIs

October 2021

The results of a clinical trial with MV140 in women suffering from recurrent urinary tract infections (UTI) have been presented at the ICS21 (International Continence Society) congress, as well as at the BAUS21 (British Association of Urological Surgeon), EAU21 (European Association of Urology) and AUA21 (American Urological Association). The study (phase III) has been carried out in several centers in Spain and the United Kingdom, including 240 patients in the active group and placebo.
More info

MV140 and autovaccines against rUTIs in elderly patients

October 2021

According to a study published in Vaccine on a population of elderly people with recurrent urinary tract infections, prophylactic treatment with MV140 or with autovaccines made from a urine sample reduces the frequency of infections and improves the patients' quality of life. Comparatively, treatment with MV140 was superior to that obtained with autovaccines.
More info

MV130 in the prevention of exacerbations in COPD

September 2021

The first results with MV130 in COPD patients have been presented at the European Respiratory Society (ERS) congress, showing its efficacy in reducing the number and intensity of exacerbations associated with this disease. The phase 3 study has been conducted in 7 hospitals including 198 patients that were followed during 18 months.
More info

Peach tree pollen allergy and peach tolerance

Alergia ocupacional al polen de melocotoneroAugust 2021

According to a study published in PLOS One, allergic patients with respiratory symptoms to peach tree pollen through their sensitization by Pru p 9 can tolerate the consumption of this fruit even if they are sensitized by Pru p 3, the main peach fruit allergen. This study, coordinated by Dr. Miguel Blanca, has been performed with the contribution of INMUNOTEK.
More info

AJRCCM publishes MV130 study

MV130August 2021

AJRCCM publishes in its August issue the results of the efficacy of MV130 in the prevention of recurrent wheezing attacks in young children. This is a randomized, double-blind, placebo-controlled phase 3 clinical trial conducted in two hospitals in Spain. The results are highlighted in an Editorial, which points out its importance as a new therapeutic option for the prevention of these processes and the implication of innate immune training as a possible mechanism of action.
More info

Allergoids coupled to mannan reprogram human monocytes

Conjugados alergoidesJuly 2021

The Journal of Allergy and Clinical Immunology publishes a study showing that mannan-allergoid conjugates reprogram human monocytes to facilitate their differentiation into tolerogenic dendritic cells. These results allow a better understanding of the cellular and molecular mechanisms of novel allergy vaccines based on these glycoconjugates.
More info

MV130/MV140 in infections under immunosuppressive treatment

MV130 MV140June 2021

According to a study published in Frontiers in Immunology, MV130 (Bactek) and MV140 (Uromune) reduce respiratory and urinary tract infections, respectively, in patients with systemic autoimmune diseases under immunosuppressive therapy. The decrease in infections in patients treated with MV130/MV140 is associated with reduced antibiotic consumption, unscheduled hospital visits and hospitalizations.
More info